{ "week": "2026-W39", "label": "Week 39 \u2014 September 27\u20133, 2026", "week_start": "2026-09-27", "generated": "2026-09-28", "stats": { "total_entries": 1371, "new_this_week": 49, "compounds_represented": 8 }, "by_compound": { "psilocybin": [ { "id": "b66c1897f831131fbde828256684a3f0ffa07b81c5c53314bca231146ac2eecc", "title": "A Randomized, Double-Blind, Placebo-Controlled Single-Ascending-Dose Study to Identify a Subperceptual Dose of Psilocybin in Healthy Adults.", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "anxiety", "sample_size": null, "status": "published", "date": "2026-09-21", "abstract": "Background/Objectives: Psilocybin shows therapeutic promise for several psychiatric disorders, but the acute perceptual and cognitive alterations produced by conventional doses (10-25 mg) require in-clinic supervision, which limits scalability.\u2026", "outcome_summary": null, "doi": "10.3390/ph19091496", "url": "https://pubmed.ncbi.nlm.nih.gov/42797541/", "source": "PubMed", "first_seen": "2026-09-28", "relevance": { "relevant": true, "reason": "Psilocybin dose-finding study in healthy adults for psychiatric treatment.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-28" } }, { "id": "3bf17cdd247746074fd5a3d2f2100e139b9426674a020aac9a6e16d708fbbcca", "title": "Multilevel Mechanisms and Clinical Efficacy of Psilocybin in Depression Treatment: A Systematic Review.", "compound": "psilocybin", "type": "meta_analysis", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-09-10", "abstract": "Depression, characterized by persistent low mood and anhedonia, represents a prevalent affective disorder imposing substantial medical and economic burdens. Current first-line antidepressants are limited by delayed onset and treatment resistance.\u2026", "outcome_summary": null, "doi": "10.3390/ijms27188052", "url": "https://pubmed.ncbi.nlm.nih.gov/42794483/", "source": "PubMed", "first_seen": "2026-09-28", "relevance": { "relevant": true, "reason": "Systematic review of psilocybin for depression treatment.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-28" } }, { "id": "806a206263a28043cd86cf3944e7164c92c35a130f61b9f6f1e5b8c8289a0c46", "title": "Mystical but not challenging experiences predict symptom improvement after psilocybin for treatment-resistant OCD.", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-01-01", "abstract": "Psilocybin treatment has shown promise across a range of psychiatric conditions. Mystical-type experiences during dosing sessions have been shown to predict the clinical effects of psilocybin treatment in depression, anxiety, and addiction.\u2026", "outcome_summary": null, "doi": "10.3389/fpsyt.2026.1799543", "url": "https://pubmed.ncbi.nlm.nih.gov/42775190/", "source": "PubMed", "first_seen": "2026-09-28", "relevance": { "relevant": true, "reason": "Psilocybin for treatment-resistant OCD and psychiatric conditions.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-28" } }, { "id": "4bb9d2f8ce9c0dfb0c0b474264d38db1bf8210fd5bbf6d1a2101ac0d0d12c726", "title": "Reply to 'Methodological concerns and interpretative limitations of assessing subjective effects of ketamine'.", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-09-22", "abstract": "This response addresses methodological concerns raised regarding our meta-analysis of subjective effects and therapeutic outcomes following ketamine and psilocybin treatment.\u2026", "outcome_summary": null, "doi": "10.1038/s44184-026-00241-2", "url": "https://pubmed.ncbi.nlm.nih.gov/42773206/", "source": "PubMed", "first_seen": "2026-09-28", "relevance": { "relevant": true, "reason": "Meta-analysis of subjective effects and therapeutic outcomes of ketamine/psilocybin.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-28" } }, { "id": "be7589268e859adc671323ded6dcb844477eadd93bfc575f89ba5c19f62a7652", "title": "Exploring the Therapeutic Potential of Psilocybin: A Comprehensive Review of Clinical Trial Evidence and Implications for Rescheduling.", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-09-18", "abstract": "Psilocybin, a compound found in certain species of Psilocybe mushrooms, shows potential as a treatment for various psychiatric conditions.\u2026", "outcome_summary": null, "doi": "10.2174/0113895575443239260828094859", "url": "https://pubmed.ncbi.nlm.nih.gov/42770437/", "source": "PubMed", "first_seen": "2026-09-28", "relevance": { "relevant": true, "reason": "Review of psilocybin for psychiatric conditions and rescheduling.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-28" } }, { "id": "a24942186265c564acd907a8787d4cf3ed30c228914bf52d9c17bb0d0ed15dcf", "title": "Qualitative Research on Psilocybin-Assisted Psychotherapy for the Treatment of Mental Disorders: A Scoping Review.", "compound": "psilocybin", "type": "meta_analysis", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-03-01", "abstract": "Psilocybin-assisted psychotherapy (PAP) may be an effective intervention for a range of mental disorders. However, there appears to be a relative lack of qualitative evidence to complement emerging quantitative findings.\u2026", "outcome_summary": null, "doi": "10.1177/28314425251394012", "url": "https://pubmed.ncbi.nlm.nih.gov/42769916/", "source": "PubMed", "first_seen": "2026-09-28", "relevance": { "relevant": true, "reason": "Qualitative review of psilocybin for mental disorders.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-28" } }, { "id": "ea15ec0489c3ff98f7b94792cd155285a603639a02c1c6fe403845e5efe9c290", "title": "Pharmacokinetics and safety of a modified-release psilocybin formulation: A SAD Phase I trial in normal-weight and overweight/obese participants.", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-09-21", "abstract": "This study aimed to evaluate the safety, tolerability and pharmacokinetics of a novel oral modified-release psilocybin formulation (REL-P11) in normal-weight and overweight/obese healthy adults and to assess its suitability for controlled, subperceptual exposure, in light of emerging evidence supporting serotonergic modulation in metabolic disorders.\u2026", "outcome_summary": null, "doi": "10.1002/bcp.70839", "url": "https://pubmed.ncbi.nlm.nih.gov/42767271/", "source": "PubMed", "first_seen": "2026-09-28", "relevance": { "relevant": true, "reason": "Phase I trial of psilocybin pharmacokinetics and safety.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-28" } }, { "id": "590e6e356add14d602cdbb9c469c151a3e4ec75e3151aa24fa7c071f7c7840d5", "title": "The serotonin 1B receptor as a target for the treatment of depression and anxiety.", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-09-21", "abstract": "Depressive and anxiety disorders impose a substantial public health burden, yet current serotonergic therapies are limited by delayed onset, modest remission rates, and adverse side effects.\u2026", "outcome_summary": null, "doi": "10.1080/14728222.2026.2738183", "url": "https://pubmed.ncbi.nlm.nih.gov/42766349/", "source": "PubMed", "first_seen": "2026-09-28", "relevance": { "relevant": true, "reason": "Targets depression and anxiety, key psychiatric indications.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-28" } }, { "id": "bc5704cbe53f8f031b5b451d5b3f41a3bd8f95768b02f9d30189743e38e48acb", "title": "An Open-Label, Dose-Escalation Trial of Psilocybin-Assisted Therapy for Bipolar II Depression.", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-09-21", "abstract": "Individuals with bipolar II disorder (BD-II) and depression face limited treatment options and are often excluded from psilocybin therapy trials due to concerns about precipitating mania or psychosis.\u2026", "outcome_summary": null, "doi": "10.4088/JCP.25m16227", "url": "https://pubmed.ncbi.nlm.nih.gov/42765891/", "source": "PubMed", "first_seen": "2026-09-28", "relevance": { "relevant": true, "reason": "Psilocybin for bipolar II depression in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-28" } }, { "id": "d13c48d258f952771c1140a22918d25ceae0f7726349c4f69a05e1e2ee5ce6ea", "title": "Psilocybin-facilitated Treatment for Chronic Pain", "compound": "psilocybin", "type": "observational", "institution": "University of Alabama at Birmingham", "condition": "other", "sample_size": 30, "status": "recruiting", "date": "2023-11-01", "abstract": "The primary purpose of this study is to preliminarily estimate the efficacy of psilocybin-facilitated treatment for fibromyalgia.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT05068791", "source": "ClinicalTrials.gov", "first_seen": "2026-09-28", "relevance": { "relevant": true, "reason": "Psilocybin for chronic pain (fibromyalgia) in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-28" } }, { "id": "90d42774e5f16e04bca216edd488bbc8c42bf4e083ba35897e803309698d9711", "title": "Mindfulness-Assisted Psychedelic Therapy", "compound": "psilocybin", "type": "phase_2", "institution": "University of Southern California", "condition": "other", "sample_size": 40, "status": "recruiting", "date": "2025-07-30", "abstract": "The goal of this clinical trial is to test psilocybin in combination with mindfulness training in healthy adults.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT06233344", "source": "ClinicalTrials.gov", "first_seen": "2026-09-28", "relevance": { "relevant": true, "reason": "Psilocybin in combination with mindfulness training in healthy adults.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-28" } }, { "id": "cd933d5c10312f40b2b83f0e39ea36e2c56bbe1713a7a1fef0eb907ab0e47e27", "title": "Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant Depression", "compound": "psilocybin", "type": "observational", "institution": "Joshua Rosenblat", "condition": "depression", "sample_size": 65, "status": "recruiting", "date": "2026-07-01", "abstract": "Psilocybin-assisted psychotherapy requires a lot of resources, with more psychotherapy being provided to integrate the meanings and insights derived from the psilocybin dosing sessions.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT07737990", "source": "ClinicalTrials.gov", "first_seen": "2026-09-28", "relevance": { "relevant": true, "reason": "Psilocybin for treatment-resistant depression.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-28" } }, { "id": "9f0b17dcd2b25769f42e1e78a6f70f1fdd1890cca72c15eb30364d2e834170ae", "title": "Red Light Holland Highlights Publication of Randomized Clinical Trial Showing a Single Dose of Psilocybin Reduced Cocaine Use, with Filament Health Holding the Exclusive License to the Data and Intellectual Property", "compound": "psilocybin", "type": "phase_2", "institution": "University of Alabama at Birmingham", "condition": "addiction", "sample_size": null, "status": "published", "date": "2026-09-16", "abstract": "Peer-reviewed results published yesterday (May 7, 2026) in JAMA Network Open demonstrate that a single dose of psilocybin meaningfully reduced cocaine use in adults with cocaine use disorder over six months, with no serious adverse events Filament Health Corp., a wholly-owned subsidiary of Red Light Holland, holds the exclusive worldwide license to the trial data and certain associated intellectual property, with the goal of supporting future regulatory authorization [...] The trial: \"Psilocybin in the Treatment of Cocaine Use Disorder: A Randomized Clinical Trial\" (Hendricks PS, Lappan SN, Shelton RC, et al.\u2026", "outcome_summary": "A single dose of psilocybin resulted in a statistically significant and sustained reduction in cocaine use compared to active placebo over six months in adults with cocaine use disorder, with no serious adverse events reported.", "doi": "10.1001/jamanetworkopen.2026.11029", "url": "http://www.newsfilecorp.com/release/296623/Red-Light-Holland-Highlights-Publication-of-Randomized-Clinical-Trial-Showing-a-Single-Dose-of-Psilocybin-Reduced-Cocaine-Use-with-Filament-Health-Holding-the-Exclusive-License-to-the-Data-and-Intellectual-Property", "source": "General News", "first_seen": "2026-09-28", "relevance": { "relevant": true, "reason": "Psilocybin for cocaine use disorder, a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-28" } }, { "id": "af9fd72aa1fc600a711e23af92c2308af4d64ac96c84663a8238866855105bb9", "title": "Roanoke's Carilion Clinic Wins Federal Grant to Test Whether Psilocybin Can Help People with Cocaine Addiction", "compound": "psilocybin", "type": "phase_1", "institution": "Carilion Clinic", "condition": "addiction", "sample_size": null, "status": "active", "date": "2026-06-17", "abstract": "On April 24, 2026, the U.S.\u2026", "outcome_summary": "Carilion Clinic received a federal grant to conduct an early study on psilocybin's potential to treat cocaine addiction. The treatment is still considered experimental.", "doi": null, "url": "https://www.medicaldaily.com/psilocybin-fda-priority-review-2026-compass-pathways-depression-ptsd-approval-475666", "source": "General News", "first_seen": "2026-09-28", "relevance": { "relevant": true, "reason": "Psilocybin for cocaine addiction is a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-28" } } ], "mdma": [ { "id": "d9620526501f178164e771810bbe1e3d793fcfba344c296b42449d1ebc3f75c7", "title": "Body image phenomenology in reports of psychedelic and meditative experiences: main themes and associations with body attitudes.", "compound": "mdma", "type": "phase_2", "institution": null, "condition": "eating_disorder", "sample_size": null, "status": "published", "date": "2026-01-01", "abstract": "Psychedelics and meditation can facilitate transformative experiences with acute changes in sensory processing and self-perception, but research about their relation to narrative and affective-attitudinal body image remains limited.\u2026", "outcome_summary": null, "doi": "10.1093/nc/niag062", "url": "https://pubmed.ncbi.nlm.nih.gov/42770027/", "source": "PubMed", "first_seen": "2026-09-28", "relevance": { "relevant": true, "reason": "Phenomenology of psychedelic experiences and body image attitudes.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-28" } }, { "id": "b18164a2e50ba58879186e2f41f62efe62fb47f9d4f45fe1b8e92379d99facca", "title": "MDMA-Assisted Therapy NDA Resubmitted to FDA for PTSD", "compound": "mdma", "type": "regulatory", "institution": null, "condition": "PTSD", "sample_size": null, "status": "approved", "date": "2026-08-11", "abstract": "The resubmission advances without a new phase 3 trial, with proponents arguing core efficacy and adverse event reporting remained accurate despite partial functional unblinding.\u2026", "outcome_summary": "Lykos Therapeutics resubmitted its New Drug Application (NDA) to the FDA for MDMA-assisted therapy for PTSD. The FDA had previously issued a Complete Response Letter regarding the application.", "doi": null, "url": "https://www.hcplive.com/view/mdma-assisted-therapy-nda-resubmitted-fda-ptsd", "source": "General News", "first_seen": "2026-09-28", "relevance": { "relevant": true, "reason": "MDMA-assisted therapy for PTSD is a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-28" } } ], "ketamine": [ { "id": "63b48d65ec18375b021d473867b0144be4b96dd4b007e3181f31ed49d46dfa4c", "title": "Symptom-level and network analyses of ketamine treatment in treatment-resistant depression: A pooled analysis of two randomized controlled trials.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-09-26", "abstract": "We examined symptom-level treatment effects and exploratory symptom networks after ketamine in treatment-resistant depression.\u2026", "outcome_summary": null, "doi": "10.1016/j.pnpbp.2026.111950", "url": "https://pubmed.ncbi.nlm.nih.gov/42800500/", "source": "PubMed", "first_seen": "2026-09-28", "relevance": { "relevant": true, "reason": "Ketamine for treatment-resistant depression in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-28" } }, { "id": "822f5c5e71ce94253ad72b4249886ac7f193da5facb827a1018ce88d735fca6c", "title": "Comparison of ketamine versus lignocaine intravenous infusion in refractory cancer pain: a prospective randomised double-blind controlled study.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-09-25", "abstract": "To compare the analgesic efficacy, adverse effect profile, incidence of acute pain crises and opioid-sparing effects of intravenous ketamine versus lignocaine infusions in patients with refractory cancer pain.\u2026", "outcome_summary": null, "doi": "10.1136/spcare-2026-006327", "url": "https://pubmed.ncbi.nlm.nih.gov/42791055/", "source": "PubMed", "first_seen": "2026-09-28", "relevance": { "relevant": true, "reason": "Ketamine for refractory cancer pain is a therapeutic use.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-28" } }, { "id": "8eb81f5b66ac434f525f8511e1f7ea2cc264cc92651cf1d3d1d3fe658cd1ed09", "title": "Ketamine-enhanced psychotherapy for smoking cessation: A pilot study of feasibility, safety, and clinical outcomes.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "addiction", "sample_size": null, "status": "published", "date": "2026-09-25", "abstract": "Tobacco use remains a leading preventable cause of morbidity and mortality. Although several pharmacotherapies and behavioral treatments for tobacco use disorder (TUD) exist, their overall efficacy is modest, underscoring the need for innovative treatment approaches.\u2026", "outcome_summary": null, "doi": "10.1177/02698811261488486", "url": "https://pubmed.ncbi.nlm.nih.gov/42788697/", "source": "PubMed", "first_seen": "2026-09-28" }, { "id": "9d5522b44a4773f9344f098cb05c5229b94e5b2f95f04fd76530c4b24395ff61", "title": "Integrated approaches to geriatric mental disorders: pathophysiology, interventions, and precision medicine horizons.", "compound": "ketamine", "type": "meta_analysis", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-01-01", "abstract": "The global aging demographic has precipitated a surge in late-life mental disorders (LMDs)-including late-life depression (LLD), anxiety, and behavioral and psychological symptoms of dementia (BPSD)-posing critical public health challenges.\u2026", "outcome_summary": null, "doi": "10.3389/fpsyt.2026.1946385", "url": "https://pubmed.ncbi.nlm.nih.gov/42787720/", "source": "PubMed", "first_seen": "2026-09-28", "relevance": { "relevant": true, "reason": "Geriatric mental disorders including depression and anxiety.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-28" } }, { "id": "d113f5d2cda960dae32b117eb96df94b243eee34362fd38f047a0623c2e9cb37", "title": "Intracellular Crosstalk Between NMDA and Sigma-1 Receptors: A Novel Mechanistic Insight Relevant to Neuropsychiatric Pharmacotherapy.", "compound": "ketamine", "type": "meta_analysis", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-09-17", "abstract": "Formerly recognized as an opioid receptor, the sigma-1 receptor (\u03c31R) is a multifunctional chaperone protein that plays a crucial role in regulating neuronal signaling, neuroprotection, and synaptic plasticity.\u2026", "outcome_summary": null, "doi": "10.3390/cells15181689", "url": "https://pubmed.ncbi.nlm.nih.gov/42782789/", "source": "PubMed", "first_seen": "2026-09-28", "relevance": { "relevant": true, "reason": "Mechanism of action relevant to neuropsychiatric pharmacotherapy.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-28" } }, { "id": "bcc74d432282848dc1f7d9c934eb4502cee4311439a49842ee7260d2c0d42220", "title": "Feasibility and tolerability of virtual reality during esketamine treatment: A pilot study.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-09-23", "abstract": "Ketamine/esketamine produce rapid antidepressant effects, with growing interest in how acute subjective experiences and the surrounding set and setting shape clinical outcomes.\u2026", "outcome_summary": null, "doi": "10.1016/j.jad.2026.122554", "url": "https://pubmed.ncbi.nlm.nih.gov/42778030/", "source": "PubMed", "first_seen": "2026-09-28", "relevance": { "relevant": true, "reason": "Esketamine for depression, human study on subjective experience.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-28" } }, { "id": "392945a3c889af53243b73e2e3daf0d69b6eb1b2defcc3348377f7e47841fc6a", "title": "Real-World Therapeutic Use of Ketamine in Clinical and Non-Clinical Settings: A Cross-Sectional Survey.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-09-23", "abstract": "The use of ketamine as a treatment for mood disorders continues to grow in popularity. However, the differences between individuals consuming ketamine within clinical settings and those self-medicating in casual, non-clinical settings has not been yet characterized.\u2026", "outcome_summary": null, "doi": "10.1080/02791072.2026.2730550", "url": "https://pubmed.ncbi.nlm.nih.gov/42776060/", "source": "PubMed", "first_seen": "2026-09-28", "relevance": { "relevant": true, "reason": "Survey of therapeutic ketamine use in clinical and non-clinical settings.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-28" } }, { "id": "c0b9f556ec3e086b1737691c7d6e179b865c2d16398b2ed6072e263d3aa11d0e", "title": "Matters arising: Methodological concerns and interpretative limitations of assessing subjective effects of ketamine.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-09-22", "abstract": "The letter addresses critical issues in the methodology and conclusions of the meta-analysis, including inconsistencies in study design, methodological flaws in comparing correlation coefficients, and discrepancies in reported results and their interpretation.\u2026", "outcome_summary": null, "doi": "10.1038/s44184-026-00240-3", "url": "https://pubmed.ncbi.nlm.nih.gov/42773216/", "source": "PubMed", "first_seen": "2026-09-28", "relevance": { "relevant": true, "reason": "Methodological concerns in assessing subjective effects of ketamine.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-28" } }, { "id": "aaa1bcb59359dd0212839a6551d5db614a6088ac46b999043fde7f1acf1a122d", "title": "Esketamine For the Treatment of Depression in a Patient With Multiple Sclerosis.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-09-22", "abstract": null, "outcome_summary": null, "doi": "10.4088/PCC.26cr04246", "url": "https://pubmed.ncbi.nlm.nih.gov/42771694/", "source": "PubMed", "first_seen": "2026-09-28", "relevance": { "relevant": true, "reason": "Esketamine for depression in a patient with MS.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-28" } }, { "id": "76e6ba99ddbaf0c0248a1699d4572067345908cfd4537ec556960a197370a905", "title": "Hippocampal miR-34a/SIRT1 and BDNF Responses Following Adolescent Stress: Differential Effects of Ketamine and Fluoxetine.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-01-01", "abstract": "Early life stress is a well-established risk factor for psychiatric disorders in adulthood; however, the underlying molecular mechanisms remain unclear.\u2026", "outcome_summary": null, "doi": "10.5080/u27776", "url": "https://pubmed.ncbi.nlm.nih.gov/42768876/", "source": "PubMed", "first_seen": "2026-09-28", "relevance": { "relevant": true, "reason": "Investigates ketamine's effects on molecular mechanisms related to psychiatric disorders.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-28" } }, { "id": "c95a9ec89a91846c55cd9c8df26a44bb801e31320c7352be3749f159337f443b", "title": "Modulation of GABA and glutamate by ketamine in depression: A systematic review and meta-analysis of magnetic resonance spectroscopy studies.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-09-21", "abstract": "Disrupted excitation-inhibition (E/I) balance involving GABA and glutamate (Glu) is implicated in the pathophysiology of depression.\u2026", "outcome_summary": null, "doi": "10.1038/s41386-026-02562-4", "url": "https://pubmed.ncbi.nlm.nih.gov/42768091/", "source": "PubMed", "first_seen": "2026-09-28", "relevance": { "relevant": true, "reason": "Ketamine for depression, a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-28" } }, { "id": "45d67b46e39441c636d6133b8129d57feff7aa7bb64e99d7ca340095afdfdb5a", "title": "Implementation and Preliminary Evaluation of an Intravenous Ketamine Protocol for Psychiatric Conditions in Medical and Surgical Units: A One-Year Pilot Study.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-09-21", "abstract": "Ketamine is an emerging therapy in psychiatry, but its implementation in the general hospital setting remains limited due to monitoring requirements, personnel allocation, and safety concerns in medically complex patients.\u2026", "outcome_summary": null, "doi": "10.1016/j.jaclp.2026.09.005", "url": "https://pubmed.ncbi.nlm.nih.gov/42767564/", "source": "PubMed", "first_seen": "2026-09-28", "relevance": { "relevant": true, "reason": "Ketamine used for psychiatric conditions in a hospital setting.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-28" } }, { "id": "8394872d0f8865eb88f6c74278be185fe5d60df94f00a547c45b857e1d5f73fd", "title": "Default mode network functional connectivity following treatment with conventional antidepressants and (es)ketamine in major depressive disorder: A systematic review.", "compound": "ketamine", "type": "meta_analysis", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-09-17", "abstract": "Antidepressant treatments, including conventional antidepressants and (es)ketamine, may reverse default mode network (DMN) resting-state functional connectivity (rsFC) alterations related to major depressive disorder (MDD).\u2026", "outcome_summary": null, "doi": "10.1016/j.pscychresns.2026.112333", "url": "https://pubmed.ncbi.nlm.nih.gov/42767040/", "source": "PubMed", "first_seen": "2026-09-28", "relevance": { "relevant": true, "reason": "Systematic review of (es)ketamine for major depressive disorder.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-28" } }, { "id": "cd5aa93e2928b44a9d4897f5f083fd69bf8c0a19c6442fc8741492f4fb25f314", "title": "Ketamine Associated ACC GABA and Glutamate Change and Depression Remission:", "compound": "ketamine", "type": "observational", "institution": "Mayo Clinic", "condition": "depression", "sample_size": 18, "status": "active", "date": "2019-01-03", "abstract": "This is a feasibility study and the goal of this project is to evaluate whether peak ACC GABA and glutamate, quantified as a CSF-corrected absolute concentration percent change from baseline, is associated with clinical remission, Montgomery Asberg Depression Rating Scale (MADRS) total score of \\<10, to the anti-glutamatergic antidepressant ketamine.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT03573349", "source": "ClinicalTrials.gov", "first_seen": "2026-09-28", "relevance": { "relevant": true, "reason": "Ketamine for depression remission, measuring GABA/glutamate changes.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-28" } }, { "id": "e0eab9a3039a05db2c863f9560bad542090932031e5a45aeefbd7ec0d2898e6d", "title": "Treatment Study of Bipolar Depression", "compound": "ketamine", "type": "observational", "institution": "Icahn School of Medicine at Mount Sinai", "condition": "depression", "sample_size": 1, "status": "completed", "date": "2009-07-01", "abstract": "The purpose of this study is to determine whether a single intravenous administration of an N-methyl-D-aspartate antagonist is safe and effective for the acute treatment of bipolar depression.", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT00947791", "source": "ClinicalTrials.gov", "first_seen": "2026-09-28", "relevance": { "relevant": true, "reason": "Investigational treatment for bipolar depression.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-28" } }, { "id": "abc015af5c46c284f5fce6c9c274947574d5b3bac1844f634e2a9639339cbdbc", "title": "Ketamine-Induced Brain Changes and Their Modulation by Lamotrigine", "compound": "ketamine", "type": "observational", "institution": "Charite University, Berlin, Germany", "condition": "other", "sample_size": 75, "status": "completed", "date": "2020-03-10", "abstract": "This study is firstly designed to investigate acute and delayed effects of a single dose of ketamine on functional brain changes during emotional and cognitive challenges and at rest.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT04156035", "source": "ClinicalTrials.gov", "first_seen": "2026-09-28", "relevance": { "relevant": true, "reason": "Investigates ketamine's effects on brain changes in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-28" } }, { "id": "86087f17550302af0247946ec3dc0aae6591bc9f559fc0ce84f996dabe5ef504", "title": "Ketamine Treatment for PTSD and MDD in TBI", "compound": "ketamine", "type": "phase_2", "institution": "Minneapolis Veterans Affairs Medical Center", "condition": "depression", "sample_size": 40, "status": "recruiting", "date": "2024-03-01", "abstract": "The goal of this clinical trial is to examine the use of sedative ketamine to treat depression and post-traumatic stress disorder (PTSD) in Veterans with mild to moderate traumatic brain injury (TBI).\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT06228391", "source": "ClinicalTrials.gov", "first_seen": "2026-09-28", "relevance": { "relevant": true, "reason": "Ketamine for PTSD and MDD in Veterans with TBI", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-28" } }, { "id": "5f3a2222dd66fb8f42ee42cd243399b54b4529f7f9484677a8c70ae82e5e2e52", "title": "Anhedonia, Development, and Emotions: Phenotyping and Therapeutics", "compound": "ketamine", "type": "observational", "institution": "Erika Forbes", "condition": "depression", "sample_size": 123, "status": "completed", "date": "2022-07-22", "abstract": "The goal of the ADEPT Study is to understand anhedonia in young people and how it changes based on treatments targeting the brain circuit underlying it. Anhedonia is a challenging mental health symptom that involves difficulty with motivation to experience pleasant events.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT05487885", "source": "ClinicalTrials.gov", "first_seen": "2026-09-28", "relevance": { "relevant": true, "reason": "Anhedonia is a psychiatric indication, and the study targets brain circuits.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-28" } }, { "id": "6b5c1a019284058ec837210b833dd49a6dad35eab70ccf01b3b483d3c3785d09", "title": "InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression", "compound": "ketamine", "type": "phase_3", "institution": "Sunnybrook Health Sciences Centre", "condition": "depression", "sample_size": 31, "status": "recruiting", "date": "2026-05-03", "abstract": "Depression is a common condition, with serious negative effects on the health and quality of life of those affected. While there are currently various medications which attempt to treat depression, they often take a long time to begin to work and do not work at all for many people.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT06781697", "source": "ClinicalTrials.gov", "first_seen": "2026-09-28", "relevance": { "relevant": true, "reason": "Ketamine for depression is a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-28" } }, { "id": "50f84a133deb8a8228576ae584408eff62346efda0257603e050ecc0782df5c3", "title": "Behavioural Activation Therapy and Ketamine for Treatment-Resistant Depression", "compound": "ketamine", "type": "phase_2", "institution": "The Royal's Institute of Mental Health Research", "condition": "depression", "sample_size": 60, "status": "recruiting", "date": "2026-09-01", "abstract": "The goal of this clinical trial is to see if combining ketamine with behavioral activation (BA) therapy to treat moderate to severe treatment-resistant depression improves depressive symptoms and general functioning more than ketamine alone.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT07801703", "source": "ClinicalTrials.gov", "first_seen": "2026-09-28", "relevance": { "relevant": true, "reason": "Ketamine for treatment-resistant depression in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-28" } }, { "id": "975dc7c2cd150b79c5639368d5675a9666cd397e889a6de680fe1c28d7b1184f", "title": "Ketamine for OUD and Suicidal Ideation in the ED", "compound": "ketamine", "type": "phase_2", "institution": "Brigham and Women's Hospital", "condition": "addiction", "sample_size": 4, "status": "completed", "date": "2024-06-14", "abstract": "This is a pilot, double-blind, placebo-controlled randomized clinical trial of individuals with opioid use disorder (OUD) with suicidal ideation in the emergency department (ED) to receive either a single infusion of ketamine 0.8mg/kg (n=25) or saline placebo (n=25).\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT06111339", "source": "ClinicalTrials.gov", "first_seen": "2026-09-28", "relevance": { "relevant": true, "reason": "Ketamine for OUD and suicidal ideation in the ED", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-28" } } ], "lsd": [ { "id": "0c255a2402cac0e00ecefd2d460892195f2980593a217531ca462b60d78097b7", "title": "Definium\u2019s psychedelic prospects brighten further on Phase III success", "compound": "lsd", "type": "phase_3", "institution": "Definium Therapeutics", "condition": "anxiety", "sample_size": null, "status": "completed", "date": "2026-08-13", "abstract": "Skip to site menu Skip to page content CTA News # Definium\u2019s psychedelic prospects brighten further on Phase III success DT120 has now posted positive results in both GAD and MDD, setting the stage for its potential foray into the neuropsychiatric market.\u2026", "outcome_summary": "DT120, a formulation of lysergide (LSD), demonstrated a statistically significant 5.4-point average decrease in anxiety scores (HAM-A) compared to placebo in a Phase III trial for generalized anxiety disorder (GAD). Benefits were observed as early as day two and sustained throughout the 12-week treatment period.", "doi": "NCT06741228", "url": "https://www.clinicaltrialsarena.com/news/definium-dt120-psychedelic-phase-iii-gad-results", "source": "General News", "first_seen": "2026-09-28", "relevance": { "relevant": true, "reason": "Phase III trial of LSD for generalized anxiety disorder", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-28" } } ], "dmt": [ { "id": "ecfb74ad68567389c7d1a06978156cad21e3ff6178c81162197abc60e7ab23bc", "title": "N,N-Dimethyltryptamine and harmine formulation alters transient EEG topography sequences near the peak of the psychedelic state.", "compound": "dmt", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-09-22", "abstract": "Psychoactive serotonin 5-HT2A receptor agonists are potent modulators of awareness. Influential theories propose that psychedelics alter whole-brain dynamics by increasing neural signal diversity and dynamic flexibility.\u2026", "outcome_summary": null, "doi": "10.1177/02698811261481062", "url": "https://pubmed.ncbi.nlm.nih.gov/42768932/", "source": "PubMed", "first_seen": "2026-09-28", "relevance": { "relevant": true, "reason": "EEG changes during psychedelic state in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-28" } }, { "id": "f7a6d53d658d1bad1408d8d9d3ab604c2d177b9eb05955184610c8aea69f82a4", "title": "Big Pharma is embracing psychedelic drugs for mental health", "compound": "dmt", "type": "phase_3", "institution": "AtaiBeckley", "condition": "depression", "sample_size": null, "status": "active", "date": "2026-07-19", "abstract": "Compass has created a psychedelic drug, COMP360, a synthetic form of psilocybin, that earlier this month scored strong Phase 3 results for treating TRD. The company plans to release its final Phase 3 results in the fourth quarter.\u2026", "outcome_summary": "AtaiBeckley's lead asset, BPL-003, a synthetic form of 5-MeO-DMT, is in Phase 3 trials for treatment-resistant depression. A Phase 2b study showed rapid and durable reductions in symptoms.", "doi": null, "url": "https://www.cnbc.com/2026/07/19/psychedelic-drugs-mental-health.html", "source": "General News", "first_seen": "2026-09-28", "relevance": { "relevant": true, "reason": "Psychedelic drug for treatment-resistant depression in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-28" } } ], "ibogaine": [ { "id": "529f70f0c14afb3cb5d1a65f741085187e96cef29ea78e0146e845d774b0697c", "title": "Letter to the Editor for \"Evaluating Pharmacogenomic Prescription Data in the Military Health System\": Medication-Induced CYP2D6 Inhibition Reveals a Screening Gap in Proxy-Defined Ibogaine Candidates.", "compound": "ibogaine", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-09-26", "abstract": null, "outcome_summary": null, "doi": "10.1093/milmed/usag436", "url": "https://pubmed.ncbi.nlm.nih.gov/42800901/", "source": "PubMed", "first_seen": "2026-09-28", "relevance": { "relevant": true, "reason": "Ibogaine candidates in military health system, pharmacogenomics.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-28" } } ], "ayahuasca": [ { "id": "f704d6d4857df79cda9c972c89ec16d8b13f84add0420e4d3727b010834d9985", "title": "Unveiling ayahuasca: Comprehensive Study of Botanical and Chemical Diversity.", "compound": "ayahuasca", "type": "meta_analysis", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-09-24", "abstract": "Ayahuasca is an entheogenic beverage traditionally used by Indigenous peoples and local communities throughout Amazonia. Its preparation typically involves the vine Banisteriopsis caapi and the leaves of Psychotria viridis, widely recognized as its principal ingredients.\u2026", "outcome_summary": null, "doi": "10.1016/j.jep.2026.122404", "url": "https://pubmed.ncbi.nlm.nih.gov/42785534/", "source": "PubMed", "first_seen": "2026-09-28", "relevance": { "relevant": true, "reason": "Ayahuasca is an entheogenic beverage used therapeutically.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-28" } } ], "other": [ { "id": "69a70247e49a323ab8cc6544d6b3de4c0338695931f74b56bfc52a8c986fd5e4", "title": "A Multi-Site Evaluation of a Psychedelic Medicine Curriculum for Psychiatry Trainees.", "compound": "other", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-09-23", "abstract": "Interest in psychedelic medicine is increasing, yet psychiatry trainees report limited education in this area. The authors developed a standardized curriculum and evaluated its impact on trainee knowledge and attitudes toward psychedelic medicines.\u2026", "outcome_summary": null, "doi": "10.1007/s40596-026-02444-3", "url": "https://pubmed.ncbi.nlm.nih.gov/42778871/", "source": "PubMed", "first_seen": "2026-09-28", "relevance": { "relevant": true, "reason": "Psychedelic medicine curriculum for psychiatry trainees.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-28" } }, { "id": "41c82c36eded22f6b3dcfcda05038d404592c5f2b9102438b5c923573cf446c7", "title": "Characterization of Altered Waking States of Consciousness in Healthy Humans", "compound": "other", "type": "observational", "institution": "University of Zurich", "condition": "other", "sample_size": 25, "status": "completed", "date": "2020-07-08", "abstract": "Altered waking states of consciousness and its underlying functional organization have gained increasing interest in recent years, i.e. in identifying the neural basis of consciousness.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT03853577", "source": "ClinicalTrials.gov", "first_seen": "2026-09-28", "relevance": { "relevant": true, "reason": "Healthy human studies on altered states of consciousness.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-28" } }, { "id": "eaa666205cdcb21fb69b992d9ce2876b64ca919448bad824f90f2d479c6382e3", "title": "Reflections on the Psychedelic Executive Order: The Dust Settles", "compound": "other", "type": "news", "institution": null, "condition": "PTSD", "sample_size": null, "status": "other", "date": "2026-09-23", "abstract": "

Do you wish you got into this event for free?\u2026", "outcome_summary": "This article discusses an executive order related to psychedelics and its potential implications for research, therapy, and policy. It features insights from experts in the field, including discussions on psilocybin-assisted therapy and MDMA-assisted therapy for veterans.", "doi": null, "url": "https://chacruna.net/reflections-on-the-psychedelic-executive-order-the-dust-settles/", "source": "Chacruna Institute", "first_seen": "2026-09-28", "relevance": { "relevant": true, "reason": "Discusses executive order, research, therapy, policy, and veterans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-28" } }, { "id": "f3e3e2555c1c6783e3dfd77b5da08e650a268280647b37312c6bfb58cbd0e69f", "title": "Building Tripsafe Communities: Why We Need Psychedelic Harm Reduction", "compound": "other", "type": "news", "institution": null, "condition": "other", "sample_size": null, "status": "other", "date": "2026-09-23", "abstract": "

Do you wish you got into this event for free? Become a Chacruna member and receive free or discounted access to all Community Forums, Courses, Workshops, and more!\u2026", "outcome_summary": "This article discusses the importance of psychedelic harm reduction and introduces experts in the field, including Tomislav Majic, Maha N. Mian, and Helena Aicher, who are involved in research and clinical practice related to psychedelic substances and their risks.", "doi": null, "url": "https://chacruna.net/building-tripsafe-communities-why-we-need-psychedelic-harm-reduction/", "source": "Chacruna Institute", "first_seen": "2026-09-28", "relevance": { "relevant": true, "reason": "Discusses psychedelic harm reduction and experts in the field.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-28" } }, { "id": "223884836511f803c055354e25240dc9c5b2d44a51d1a999284f97780e427f69", "title": "FDA Holds Historic Public Hearing on Psychedelic Therapies", "compound": "other", "type": "regulatory", "institution": "Food and Drug Administration", "condition": "other", "sample_size": null, "status": "other", "date": "2026-09-22", "abstract": "

On September 14, 2026, the Food and Drug Administration (FDA) convened a highly anticipated public hearing at its White Oak campus in Silver Spring, Maryland, focused squarely on provider credentialing, patient safety, data standardization, and equitable access. 

Titled \u201cConsiderations for Potential Future Therapeutic Use of Psychedelic Drugs Public Hearing,\u201d the hearing marked the beginning of a multi-day stretch of gatherings featuring federal health officials, clinical stakeholders, and drug developers coming together to map out an evolving, and sometimes contradictory, architecture for psychedelic medicine.\u2026", "outcome_summary": "The FDA convened a public hearing to discuss provider credentialing, patient safety, data standardization, and equitable access for psychedelic therapies. Stakeholders warned against over-regulation and emphasized the importance of patient choice and financially viable credentialing for providers.", "doi": null, "url": "https://www.lucid.news/fda-holds-historic-public-hearing-on-psychedelic-therapies/", "source": "Lucid News", "first_seen": "2026-09-28", "relevance": { "relevant": true, "reason": "FDA hearing on psychedelic therapies covers regulation and access.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-28" } }, { "id": "679edd963a67523397cd24b93b8a4958b0a219da39fe22992b376fc463246e31", "title": "Psychedelics get a hearing at FDA", "compound": "other", "type": "news", "institution": null, "condition": "other", "sample_size": null, "status": "other", "date": "2026-09-14", "abstract": "STONE: Pretty soon - FDA has approved treatment with another psychoactive drug, ketamine, but that's it so far. There was an effort to get MDMA approved about two years ago that was ultimately unsuccessful. The situation is a lot different now, though. Research has moved forward.\u2026", "outcome_summary": "The FDA held a hearing on the future of psychedelics in mental healthcare, with stakeholders discussing administration and provider training for drugs like psilocybin, LSD, and MDMA.", "doi": null, "url": "https://www.npr.org/2026/09/14/nx-s1-5966636/psychedelics-get-a-hearing-at-fda", "source": "General News", "first_seen": "2026-09-28", "relevance": { "relevant": true, "reason": "FDA hearing on psychedelics in mental healthcare", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-28" } }, { "id": "e2bdcbe2cfb57c7ca97d9c50b0405adada7462176f5db1741e71fe7a4709a4b4", "title": "Psychedelic drug makers rally after Trump orders FDA to expedite reviews", "compound": "other", "type": "news", "institution": null, "condition": "other", "sample_size": null, "status": "other", "date": "2026-04-20", "abstract": "U.S. President Donald Trump signs an executive order encouraging more research into ibogaine, next to U.S. Health and Human Services (HHS) Secretary Robert F.Kennedy Jr., Joe Rogan, and Americans for Ibogaine CEO W.\u2026", "outcome_summary": "The article discusses how psychedelic drug makers saw their stocks rally after former President Trump's administration ordered the FDA to expedite reviews of certain drugs. It does not report on specific clinical trial outcomes or statuses.", "doi": null, "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/psychedelic-drug-makers-rally-trump-orders-fda-expedite-reviews-2026-04-20", "source": "General News", "first_seen": "2026-09-28", "relevance": { "relevant": true, "reason": "Regulatory and industry news about psychedelic drug makers.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-28" } } ] } }